A Phase 1b Dose-Escalation and Cohort-Expansion Study of the Safety, Tolerability, and Efficacy of a Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With the Anti-PD-L1 Antibody Durvalumab (MEDI4736) in Recurrent or Refractory Metastatic Pancreatic Cancer

Trial Profile

A Phase 1b Dose-Escalation and Cohort-Expansion Study of the Safety, Tolerability, and Efficacy of a Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With the Anti-PD-L1 Antibody Durvalumab (MEDI4736) in Recurrent or Refractory Metastatic Pancreatic Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Jan 2017

At a glance

  • Drugs Durvalumab (Primary) ; Galunisertib (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 21 Jan 2017 Trial design presented at the 2017 Gastrointestinal Cancers Symposium
    • 15 Jul 2016 Status changed from not yet recruiting to recruiting.
    • 14 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top